Taking Aim at Tobacco: Highlights From Annual Meeting Symposium

The tobacco product landscape is evolving and the AACR Tobacco Products and Cancer Subcommittee has been cognizant of the shift from combusted products (e.g., cigarettes) to alternative nicotine delivery systems, such as e-cigarettes. While it is generally accepted that e-cigarettes are safer than traditional cigarettes, these products still present risks and the AACR has been active in trying to keep children from having access to them.

Read More

Educating the Public on Cancer Prevention

On Saturday, May 4, Philadelphians flooded the Benjamin Franklin Parkway for the Franklin Institute’s ninth annual Philadelphia Science Festival. For the fourth consecutive year, the American Association for Cancer Research (AACR) was a sponsor of the community event, giving eager kids and their families the opportunity to learn about science with hands-on experiments and activities.

Read More

New Horizons in Cancer Research Conference Draws to a Close

The Fifth AACR New Horizons in Cancer Research (NHiCR) international conference has concluded, and the more than 400 attendees are en route to their home countries, which included Australia, China, Colombia, Germany, Israel, Japan, Korea, Qatar, Singapore, Sweden, and the United States. 

Read More

Conference in China Examines Genomics, Drug Development

Shenzhen is a remarkable place. It serves as a gateway to Hong Kong, and in its short 40-year history has grown to become China’s seventh largest city, with a population of 20 million and some of Mainland China’s tallest buildings. The Fifth AACR New Horizons in Cancer Research (NHiCR) International Conference sessions have attracted more than 350 basic, clinical, and translational researchers and practitioners from throughout China, the Asia-Pacific region, and worldwide.

Read More

AACR Presents New Horizons in Cancer Research in Shenzhen, China

Greetings from Shenzhen, China, where the Fifth AACR New Horizons in Cancer Research (NHiCR) Conference is now underway. The event’s aim is to create and further a global forum for the communication and exchange of knowledge and latest findings in basic, translational, and clinical research and to foster cooperation and network development, leading to a decrease in global cancer incidence and mortality. The conference is co-organized through the collaborative efforts of AACR, Peking University Shenzhen Graduate School, The State Key Laboratory of Chemical Oncogenomics, and Shenzhen Bay Laboratory.

Read More

ICYMI: A Summary of Annual Meeting 2019 Blog Posts

The American Association for Cancer Research (AACR) Annual Meeting 2019 drew more than 21,000 attendees, providing a robust forum to present and discuss the latest breakthroughs in cutting-edge basic, translational, and clinical cancer research. As always, the meeting attracted some of the best minds in research and medicine, representing many facets of cancer care. Researchers, physician-scientists, policymakers, advocates, and industry representatives all played important roles in exchanging information over the course of a dynamic Annual Meeting program.

Read More

AACR Annual Meeting 2019: Past, Present, and Future of CDK4/6-targeted Therapeutics

Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard S. Finn, MD, told attendees of the Making Science Count for Patients: CDK4/6 special session during the recent AACR Annual Meeting 2019. This session was designed to review the progress made with this class of anticancer therapeutics, starting from basic science through preclinical and clinical development, and to look to what we might expect from these agents in the future.

Read More

AACR Annual Meeting 2019: Leaders Share Highlights and Future Direction

One of the world’s largest cancer research conferences, the AACR Annual Meeting 2019, came to an end with a plenary session titled “AACR Annual Meeting 2019 Highlights: Vision for the Future.” Leaders of the AACR provided an overview of the stellar presentations from the meeting on the topics of prevention, early detection, interception, and the latest breakthroughs in cutting-edge basic, translational, and clinical research.

Read More

AACR Annual Meeting 2019: Patients as Partners in the Research Process

In the past couple of decades, progress against cancer has created a new generation of survivors. Today, more than 16.9 million people in the United States are cancer survivors. While their experiences are incredibly diverse, many are living well. They work, they tend to their families, they travel … and many are inspired to play a role in the cancer research community.

The Presidential Select Symposium at the AACR Annual Meeting 2019 addressed these crucial roles in a session titled “Engaging Cancer Patients as Partners in the Research Process.” The session was moderated by outgoing AACR President Elizabeth M. Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Read More

AACR Annual Meeting 2019: New Approaches to Treating Drug-resistant Non-small Cell Lung Cancer

About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of NSCLCs harbor epidermal growth factor receptor (EGFR)-activating mutations.
Treatment for EGFR-mutant NSCLC improved dramatically with the introduction of EGFR tyrosine kinase inhibitors (TKIs). Several TKIs targeting this receptor have been developed, including the U.S. Food and Drug Administration (FDA)-approved first-generation EGFR TKIs gefitinib (Iressa) and erlotinib (Tarceva); second-generation EGFR TKIs, such as the FDA-approved afatinib (Gilotrif) and dacomitinib (Vizimpro), and the investigational therapeutic neratinib; and third-generation EGFR TKIs, including the FDA-approved osimertinib (Tagrisso), and the investigational therapeutics olmutinib and nazartinib.

Read More